4. CLINICAL PARTICULARS  
4.1 Therapeutic indications  
COMIRNATY (tozinameran) COVID-19 Vaccine has provisional approval for the indication below:  
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 5 years of age and older.

https://www.tga.gov.au/sites/default/files/covid-19-vaccine-pfizer-australia-comirnaty-tozinameran-mrna-pi.pdf

---

